valu usd unless otherwis note
increas pt slower enbrel eros
opportun nsclc
view rais pt increas out-year
enbrel sale estim integr pipelin
blockbust potenti could fill declin base busi
neulasta remain sector perform await approach
data updat better assess durabl competitor dynam
well deeper pipelin develop provid pipelin upsid
updat model reflect increas enbrel sale estim
follow recent legal victori link legal eagl note
addit includ estim valuat forecast
sale assumpt nsclc colorect cancer updat
add pt reflect slightli higher enbrel sale
estim given increas ip posit inclus
revenu stream link post-cal note
model reach peak risk unadjust sale
kra mutant nsclc kra mutant
model launch us/eu reach
peak global risk-unadjust sale risk-adjust
po across third-lin kra mutat nsclc
see nsclc import kra mutat oncolog
market target note kra mutat
occur lung cancer preval see
estim support target oncolog product
alk target therapi xalkori alecensa achiev
sale respect repres annual
run-rat alk mutat occur lung
cancer vs kra occurr lung cancer
epidemiolog suggest kra larger/mor frequent vs
nsclc durabl remain key unknown cross-compar
market preliminarili model month treatment durat nsclc
mo model price us
eu discount launch larg in-lin
target therapi alk target drug xalkori alecensa
price per month respect howev note
price upsid target therapi comp rog recent
approv inhibitor vitrakvia entrectinib price
continu pg
price prior trade day market close estimate unless otherwis note
see limit forward growth emerg
pipelin yet fill shoe amgn matur product
eros see inexpens biotech compani
rel basi like dividend perspect
steadi cash flow despit headwind base busi
despit see risk amgn recent near-
term product launch cgrp humira biosimilar
upsid slower product eros remain
sidelin
biosimilar remain major part valuationw see
amgn intern pipelin biosimilar major revenu
ep driver though remain slightli cautiou
street launch time view recent setback
humira biosimilar indic challeng launch
environ initi anticip model amgn
biosimilar launch remicad rituxan avastin
herceptin humira see launch ahead
upsid model
launch repatha upcom
focu emerg pipelin becom construct
launch
omecamtiv parsabiv key driver off-set base busi
eros see repatha uptak signific driver
close monitor rx share follow posit long-
risk greater-than-expect competit core
busi franchis lower-than-expect uptak
grow busi develop regulatori setback
bloomberg capit market estim upside/downside/target
valu dcf basi use wacc
termin growth rate view
trade appropri valu forward price-to-earnings basi vs
peer similar growth prospect discount project
revenu market product contribut
sh discount risk-adjust revenu pipelin product
contribut revenu contribut cash
contribut result price target
support sector perform rate
upsid scenario assum longer-than-
expect delay entranc biosimilar
market slower-than-expect revenu eros
base busi higher-than-expect uptak repatha
downsid scenario assum faster-than-
expect market entri biosimilar lead greater
market share eros price pressur
base busi regulatory/litig setback
biosimilar franchis continu slow uptak repatha
limit current estim opportun in-lin top-lin data
present link prez note patient
treat line therapi see potenti upsid data emerg
clinic advanc earlier treatment set nsclc repres largest potenti
market model peak us/eu risk-unadjust sale
peak global sale model assumpt leav room competit
space peak penetr preval patient model slightli smaller
opportun peak global sale estim similar competit model peak
penetr
significantli larger opportun exist earlier treatment paradigm
retain upsid pend data readout patient initi estim
limit launch third-lin set see potenti much larger opportun
data matur approv sought earlier line treatment across diseas
target therapi lung cancer histor demonstr similar respons rate across
line therapi warrant optim expans across line therapi abstract
iaslc releas today august et expect see first data readout
nsclc monotherapi expans cohort get clearer pictur earliest
opportun look like
increas out-year enbrel estim follow amgn legal victori increas
out-year enbrel estim reflect possibl
ultim prevail on-going litig sandoz/nv appeal amgn recent win
nj court larg remov major overhang thesi enbrel
estim remain somewhat suppress due remain legal risk-adjust price
pressur increas competit space
valu dcf basi use wacc termin growth rate
view trade appropri valu forward price-to-earnings basi vs peer
similar growth prospect discount project revenu market product
contribut discount risk-adjust revenu pipelin product contribut
revenu contribut cash contribut result
sh price target support sector perform rate
risk rate price target
factor neg influenc valuat rate greater-than-expect
competit core busi franchis lower-than-expect uptak
grow busi develop regulatori setback late-stag pipelin
global biotechnolog compani focus develop manufactur
commerci novel biotherapeut primarili cancer nephrolog inflammatori
diseas cardiovascular diseas bone diseas pioneer use
recombin dna produc world success blockbust biotech drug
compani core busi erythropoietin epo stimul agent esa
epogen aranesp neutrophil stimul neulasta franchis
obtain princip inflammatori diseas busi enbrel acquisit
immunex go forward compani primari futur growth driver repatha
compani report capit market estim
chang model revenu expens mm expens mm expens mm incom mm incom mm incom mm non-gaap ep exhibit incom statement
compani report capit market estim
incom base total product product product cost expens non oper incom ebit non incom tax tax net ep ep ep ep exhibit dcf valuat
compani report capit market estim
dollar mm except per-shar data discount add add effect add termin exhibit price target breakdown
compani report capit market estim
